Literature DB >> 10636065

Gastrointestinal motility in patients with irritable bowel syndrome studied by using radiopaque markers.

Y Horikawa1, H Mieno, M Inoue, G Kajiyama.   

Abstract

BACKGROUND: Irritable bowel syndrome (IBS) has been identified as a physiologic abnormality, but no test has been established as a diagnostic standard for gastrointestinal dyskinesia in IBS patients. The aim of this study was to investigate gastrointestinal motility in patients with IBS by using radiopaque markers.
METHODS: Gastrointestinal motility was studied in IBS patients (n = 72), constipation patients (n = 19), diarrhoea patients (n = 9), and healthy controls (n = 23). Using three types of radiopaque markers, analysis was performed to establish the transit time and a new indicator, the 'scattering index'.
RESULTS: Transit times were not characteristic in IBS. The patients with IBS had significantly higher scattering indexes in the colon and total gut than the healthy controls and the patients with constipation and diarrhoea. The transit time and scattering index of the colon were linearly correlated in the healthy controls and the constipation and diarrhoea patients but were not correlated in the IBS patients. Using transit time and scattering index was a reliable means of evaluating gastrointestinal motility in IBS patients, with a sensitivity of 65% and a specificity of 96%.
CONCLUSION: Three days' use of the radiopaque marker method was useful for providing an objective means of detecting gastrointestinal dysmotility in IBS patients.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10636065     DOI: 10.1080/003655299750024698

Source DB:  PubMed          Journal:  Scand J Gastroenterol        ISSN: 0036-5521            Impact factor:   2.423


  13 in total

Review 1.  Challenges to the therapeutic pipeline for irritable bowel syndrome: end points and regulatory hurdles.

Authors:  Michael Camilleri; Lin Chang
Journal:  Gastroenterology       Date:  2008-10-09       Impact factor: 22.682

2.  Probiotic therapy for irritable bowel syndrome.

Authors:  George Aragon; Deborah B Graham; Marie Borum; David B Doman
Journal:  Gastroenterol Hepatol (N Y)       Date:  2010-01

Review 3.  The role of experimental models in developing new treatments for irritable bowel syndrome.

Authors:  Daniel P Holschneider; Sylvie Bradesi; Emeran A Mayer
Journal:  Expert Rev Gastroenterol Hepatol       Date:  2011-02       Impact factor: 3.869

4.  Asian motility studies in irritable bowel syndrome.

Authors:  Oh Young Lee
Journal:  J Neurogastroenterol Motil       Date:  2010-04-27       Impact factor: 4.924

Review 5.  Functional GI disorders: from animal models to drug development.

Authors:  E A Mayer; S Bradesi; L Chang; B M R Spiegel; J A Bueller; B D Naliboff
Journal:  Gut       Date:  2007-10-26       Impact factor: 23.059

Review 6.  Irritable bowel syndrome: the evolution of multi-dimensional looking and multidisciplinary treatments.

Authors:  Full-Young Chang
Journal:  World J Gastroenterol       Date:  2014-03-14       Impact factor: 5.742

Review 7.  Studying the overlap between IBS and GERD: a systematic review of the literature.

Authors:  Igor Nastaskin; Edgar Mehdikhani; Jeffrey Conklin; Sandy Park; Mark Pimentel
Journal:  Dig Dis Sci       Date:  2006-11-01       Impact factor: 3.487

Review 8.  Optimal management of constipation associated with irritable bowel syndrome.

Authors:  Manuele Furnari; Nicola de Bortoli; Irene Martinucci; Giorgia Bodini; Matteo Revelli; Elisa Marabotto; Alessandro Moscatelli; Lorenzo Del Nero; Edoardo Savarino; Edoardo G Giannini; Vincenzo Savarino
Journal:  Ther Clin Risk Manag       Date:  2015-05-30       Impact factor: 2.423

9.  Drug development for the irritable bowel syndrome: current challenges and future perspectives.

Authors:  Fabrizio De Ponti
Journal:  Front Pharmacol       Date:  2013-02-01       Impact factor: 5.810

10.  Novel MRI tests of orocecal transit time and whole gut transit time: studies in normal subjects.

Authors:  G Chaddock; C Lam; C L Hoad; C Costigan; E F Cox; E Placidi; I Thexton; J Wright; P E Blackshaw; A C Perkins; L Marciani; P A Gowland; R C Spiller
Journal:  Neurogastroenterol Motil       Date:  2013-10-25       Impact factor: 3.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.